Skip to content

Change in AP at other companies

Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$2.71M+226%
Theravance Biopharma logo
Theravance BiopharmaTBPH
-$1.47M-984%
Innoviva, Inc. logo
Innoviva, Inc.INVA
$1.55M-39.6%
Zymeworks logo
ZymeworksZYME
-$7.75M+63.5%
ALN
Alnylam PharmaceuticalsALNY
-$176.03M-11.6%
Xencor logo
XencorXNCR
-$2.87M-405%

Other financials

Income statement

See full
Revenue$12.3M-22.6%
Operating income-$480.0K-108%
Net income$4.5M+88.6%
EPS (diluted)$0.17+183%

Balance sheet

See full
Cash & equivalents$85.6M-5.2%
Total debt$124.7M+9.0%
Total equity$92.9M+9.7%
Total assets$271.9M+27.8%

Cash flow

See full
Operating cash flow$6.1M+178%
CapEx$3.0K-29.4%
Free cash flow-$2.9M+36.0%

Valuation

See full
Market cap$746.04M+159%
Enterprise value$785.17M+152%
P/E22.1×
P/S15.4×+8.7×

Profitability

See full
Operating margin10.2%+5.5pp
Net margin69.6%+64.0pp
FCF margin-320%-118pp

Returns & leverage

See full
Return on equity38.1%+35.2pp
Debt / equity1.3×0.0×
Current ratio3.6×-2.0×

Where this comes from

Reported directly by XOMA Corporation in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.

The official record: XOMA Corporation’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about XOMA Corporation's change in ap.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is XOMA Corporation's change in AP?
XOMA Corporation (XOMA) reported change in AP of -$2.63M in Q1 2026.
How has XOMA Corporation's change in AP changed year-over-year?
XOMA Corporation's change in AP increased by 19.5% year-over-year, from -$3.27M to -$2.63M.
What does change in AP mean?
Increase or decrease in amounts owed to suppliers — a key working capital component affecting operating cash flow.